Skip to main content

Table 2 Clinicopathological data association with CDX2, MUC2 and SOX2 status in 227 patients with stage II colorectal carcinoma

From: Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients

 

CDX2

MUC2

SOX2

Low

High

P

Low

High

P

–

+

P

Patients

33

194

164

63

184

43

Age (years)

 Media

67.7 ± 11.8

68.4 ± 11.4

0.81

68.3 ± 11.7

68.2 ± 11.1

0.96

67.9 ± 11.5

69.9 ± 11.1

0.74

 Range

35–87

23–92

23–92

37–83

23–92

37–87

Sex

 Female

19

73

0.04*

65

27

0.65

72

20

0.39

 Male

14

121

99

36

112

23

Histopathological grade (n = 224; ND = 3)

 G1

0

4

< 0.001*

1

3

0.05

3

1

0.20

 G2

25

185

157

53

173

37

 G3

7

3

6

4

6

4

Tumor Location (n = 224; ND = 3)

 Proximal colon

16

59

0.09

48

27

0.13

58

17

0.22

 Distal colon

14

93

83

24

92

15

 Rectum

3

39

30

12

32

10

Mismatch repair status (n = 209; ND = 18)

 MMR-deficient

22

69

< 0.001*

68

23

0.75

77

14

0.37

 MMR-proficient

7

111

85

33

93

25

BRAFV600E (n = 216; ND = 11)

 WT

25

161

0.17

132

54

1.00

152

34

0.80

 MUT

7

23

21

9

24

6

CDX2

 Low

 

23

10

0.83

26

7

0.81

 High

141

53

158

36

MUC2

 Low

  

137

27

0.13

 High

47

16

  1. Notes. It is indicated the number of cases with low and high expression of CDX2 and MUC2 and negative (−) or positive (+) for SOX2, for all the clinicopathological categories, except age. P values (statistical significance threshold< 0.05) were obtained using Student’s t test for the continuous variable, Fisher’s exact test (2-sided) and Qui-square (χ2) test for categorical variables
  2. * indicates comparisons with P < 0.05